Tango Therapeutics
Approach
Pipeline
Leadership
Join Us
News + Events
Contact
Home
Our Approach
Pipeline
Leadership
Join Us
News + Events
Contact
EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer
Press Release
EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer